Welcome to our dedicated page for Benitec Biopharm SEC filings (Ticker: BNTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Benitec Biopharma's SEC filings provide detailed insights into the company's clinical development activities, financial condition, and strategic direction as a clinical-stage biotechnology company. The company's periodic reports, including quarterly Forms 10-Q and annual Forms 10-K, offer comprehensive disclosures about the progress of its gene therapy programs, particularly the BB-301 clinical trial for OPMD. These filings contain detailed discussions of clinical trial designs, patient enrollment status, interim results, regulatory interactions, and plans for advancing candidates through development stages.
Financial disclosures in SEC filings reveal Benitec Biopharma's cash position, operating expenses, research and development expenditures, and capital resources available to fund ongoing operations. The company's filings include detailed breakdowns of clinical trial costs, manufacturing expenses, personnel costs, and general administrative expenses. Management's discussion and analysis sections provide context about the company's liquidity, funding requirements, and strategic plans for capital allocation. Information about equity offerings, warrants, stock-based compensation, and other financing activities appears in various SEC filings.
Risk factor disclosures in SEC filings outline the uncertainties inherent in clinical-stage biotechnology development, including risks related to clinical trial outcomes, regulatory approval pathways, manufacturing scalability, intellectual property protection, and market competition. The company's filings describe the complexities of gene therapy development, including manufacturing challenges, regulatory requirements specific to genetic medicines, and the uncertainties associated with pioneering novel therapeutic modalities. Material agreements, licensing arrangements, and collaborative relationships are disclosed in exhibits and described in the body of periodic reports.
Current reports on Form 8-K announce significant corporate events such as clinical trial milestones, regulatory designations, financing transactions, executive appointments, and other material developments. Proxy statements provide information about corporate governance, board composition, executive compensation, and shareholder matters. Investors and analysts utilize these SEC filings to assess Benitec Biopharma's progress in advancing its pipeline, evaluate the company's financial sustainability, and understand the regulatory and commercial pathway for its gene therapy candidates. The filings represent the authoritative source for understanding the company's operations, risks, and strategic execution within the gene therapy and rare disease treatment sectors.
Benitec Biopharma Inc. (BNTC) reported a new stock option grant to its Chief Operating Officer, Sophie Mukadam, in an ownership filing. On 11/18/2025, she received options to purchase 500,000 shares of Benitec common stock at an exercise price of $13.53 per share, expiring on 11/18/2035. These options are scheduled to vest in 16 substantially equal quarterly installments beginning on March 31, 2026, meaning the award vests gradually over four years while she remains in her role.
Benitec Biopharma Inc. (BNTC) reported an equity award to its Chief Executive Officer and director, Jerel A. Banks, on a Form 4. On November 18, 2025, he received 450,000 stock options with an exercise price of $13.53 per share, giving him the right to buy Benitec common stock at that price.
The options have a long-term horizon, expiring on November 18, 2035. According to the filing, they will vest in 16 substantially equal quarterly installments, beginning on March 31, 2026. After this grant, Jerel A. Banks beneficially owned 450,000 stock options, held directly.
Benitec Biopharma Inc. (BNTC) reported a stock option grant to director and Chief Financial Officer Megan Boston. On 11/18/2025, she received options to purchase 200,000 shares of common stock at an exercise price of $13.53 per share, expiring on 11/18/2035.
The options will vest in 16 substantially equal quarterly installments beginning on March 31, 2026, meaning the award vests gradually over four years. The filing indicates she holds these options directly, reflecting a standard equity-based compensation grant that aligns executive incentives with shareholder interests.
Benitec Biopharma Inc. (BNTC) filed an 8‑K stating it furnished a press release with financial results for the fiscal quarter ended September 30, 2025, and an operational update. The press release is attached as Exhibit 99.1.
The company notes the information furnished under Item 2.02, including Exhibit 99.1, is not deemed filed for liability purposes and is not incorporated by reference unless expressly stated. BNTC’s common stock trades on The Nasdaq Stock Market LLC.
Benitec Biopharma (BNTC) reported quarterly results with no revenue and a net loss of $8.97 million for the three months ended September 30, 2025. Operating expenses were $9.80 million, led by R&D $3.37 million and G&A $6.43 million. Cash used in operating activities was $3.35 million.
The company ended the quarter with $94.5 million in cash and cash equivalents and stated this is sufficient to fund operations for at least the next twelve months from the date of the report. Subsequent to quarter-end, Benitec completed an underwritten offering of 5,930,000 shares at $13.50 and a concurrent registered direct sale of 1,481,481 shares at $13.50, for gross proceeds of approximately $100 million. Shares outstanding were 26,250,469 as of September 30, 2025; 33,862,226 were outstanding as of November 14, 2025. Benitec continues advancing BB-301, its silence-and-replace AAV gene therapy for OPMD, with multiple subjects treated in an ongoing Phase 1b/2a study.
Benitec Biopharma (BNTC) reported insider purchases by joint filers associated with Suvretta Capital. On 11/07/2025, the reporting persons acquired 730,370 shares of common stock at $13.5 per share and separately acquired 751,111 shares at $13.5. The holdings following these transactions were reported as 9,538,175 shares and 1,819,812 shares, respectively. The positions are listed as indirect ownership, and the filers are identified as a Director and 10% Owner. Additional explanatory notes are referenced in Exhibit 99.1.
Benitec Biopharma (BNTC) reported an insider equity award. A director received options to purchase 28,517 shares on 11/05/2025 at an exercise price of $15.78 per share. These options were granted for $0 and expire on 11/05/2035. The award will vest in full on the earlier of immediately prior to the company’s 2026 annual meeting of stockholders or November 5, 2026. Following the grant, the director holds 28,517 derivative securities directly.
Benitec Biopharma Inc. (BNTC) reported an insider ownership update. A director filed a Form 3 initial statement of beneficial ownership under Section 16. The filing states that no securities are beneficially owned.
The event date is 11/03/2025, and the form was signed by Sharon Mates on 11/07/2025. This is an administrative disclosure of initial insider status and holdings.
Benitec Biopharma Inc. (BNTC) announced two equity offerings priced at $13.50 per share. The company agreed to sell 5,930,000 shares in a firm‑commitment underwritten offering, with a 30‑day option for underwriters to buy up to 889,500 additional shares. Concurrently, it entered a registered direct sale of 1,481,481 shares to Averill funds at the same price.
Gross proceeds are expected to be approximately $100 million before fees and expenses. Underwriting and placement fees are 6.0% of gross proceeds for their respective transactions. The company, its executives and directors, and Suvretta Capital entered 90‑day lock‑ups. Closings are expected on November 7, 2025, subject to customary conditions. Proceeds are intended to support product candidate development, working capital and general corporate purposes.
Benitec Biopharma Inc. is registering and selling 7,411,481 shares of common stock at $13.50 per share. The deal combines a firm-commitment underwritten offering of 5,930,000 shares and a concurrent registered direct sale of 1,481,481 shares, both priced identically. The company has granted underwriters a 30‑day option to purchase up to 889,500 additional shares.
Gross proceeds reflect the pricing: the tables show proceeds to the company of $94,051,694 before expenses, and the company estimates net proceeds of approximately $93.6 million, or $104.9 million if the option is fully exercised. As of September 30, 2025, cash and cash equivalents were approximately $94.479 million. Shares outstanding were 26,250,469 as of June 30, 2025.
Benitec plans to use the net proceeds, together with existing cash, to fund continued development of its product candidate programs, working capital, and other general corporate purposes. The underwritten public offering and the concurrent registered direct offering are contingent on each other closing. The offering price represents a discount to the last reported price of $15.78 on November 5, 2025, and new investors will incur immediate dilution described in the filing.
FAQ
What is the current stock price of Benitec Biopharm (BNTC)?
What is the market cap of Benitec Biopharm (BNTC)?
